Testing a new osteoporosis drug for women after menopause
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial tests a new injection called abaloparatide (QLG2128) for women after menopause who have weak bones (osteoporosis) and a high risk of breaking a bone. It aims to see if it helps strengthen bones and prevent fractures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman after menopause, between 50 and 85 years old, and can walk without help.
- Your bone density at the lower back (lumbar spine) or hip is low, but not extremely low.
- You have at least one factor that makes you more likely to break a bone, such as a past break from a minor fall, a family history of hip fracture, being 70 or older, having a low body weight, or currently smoking.
- You have not had other bone diseases, bone cancer, low blood pressure when standing up, or active kidney stones recently.
- You have not used certain osteoporosis treatments or medications affecting bones in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication called SAL056 to strengthen bones and prevent fractures in postmenopausal women with osteoporosis. Researchers want to find the best dose and how often to give it.
This trial tests a new medication, QL1206, against an approved drug, Prolia, to see if it works as well for treating osteoporosis in postmenopausal women. You may be eligible if you have low bone density and at least one risk factor for fractures.
This study looks at ways to prevent and treat “brittle bone” refractures after a recent fracture in people with osteoporosis. If you’ve had a new hip, spine, or other bone fracture, the trial may test strategies to lower the chance of another fracture.
This study tests two injectable medications (romosozumab and abaloparatide) that help strengthen bones in women after menopause. Researchers will also look at blood markers to understand why some women respond better to treatment than others.
This study tests how a bone-strengthening medication called Abaloparatide affects the quality of bones in your lower spine. Researchers will use imaging scans to see if the medication helps improve bone strength in people with osteoporosis who also have spine wear-and-tear.
This trial tests teriparatide (a hormone-like bone medicine) to improve bone health in people with advanced chronic kidney disease who are at risk for weak, low-turnover bone. It may help by changing how quickly your bones break down and rebuild.
Hear when a new Postmenopausal Women With Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.